Epidemiological Characteristics,<i>EGFR</i>Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study

Syrigos, Konstantinos; Georgoulias, Vasilis; Zarogoulidis, Konstantinos; Makrantonakis, Paris; Charpidou, Andriani

doi:10.21873/anticanres.12654

Cited by 12 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the right upper lobe was the most frequent mass location for both cancer and cancer-free patients. Similar results were found in an earlier analysis of bronchoscopic data in Northern Greece 18 , as well as in the Greek REASON observational Registry Study on a small number of patients 29 concerning the location of the malignancy. In our study, the most common tumor sites were found to be the upper lobes; a plausible explanation could be that the upper lobes are more affected by tobacco smoking 30 .…”

Section: Discussionsupporting

confidence: 89%

Epidemiology of lung cancer in Northern Greece: An 18- year hospital-based cohort study focused on the differences between smokers and non-smokers

Domvri¹,

Porpodis²,

Zisi³

et al. 2020

Tob. Induc. Dis.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Epidemiology of lung cancer in Northern Greece: An 18- year hospital-based cohort study focused on the differences between smokers and non-smokers

Domvri¹,

Porpodis²,

Zisi³

et al. 2020

Tob. Induc. Dis.

View full text Add to dashboard Cite

“…Of the patients at IPO-Porto with NSQ who were tested for EGFR or ALK mutations/rearrangements, 20.1 and 8.8%, respectively, were found to have mutations/rearrangements. These rates are comparable to those reported in several observational studies conducted in Portugal and elsewhere in Europe in which rates ranged from 10 to 28% for EGFR mutations [15][16][17][18][23][24][25][26][27], and from 3 to 12% for ALK rearrangements [17,24].…”

Section: Discussionsupporting

confidence: 87%

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

et al. 2020

View full text Add to dashboard Cite

Background As part of the multinational I-O Optimise research initiative, this retrospective cohort study of patients with advanced non-small cell lung cancer (NSCLC) evaluated real-world treatment patterns and survival prior to immunotherapy reimbursement in Portugal. Methods This study utilized a database held by IPO-Porto, Portugal’s largest oncology hospital. Adult patients diagnosed with stage IIIB or IV NSCLC from January 2012 to December 2016 at IPO-Porto, with follow-up to June 2017, were included. Treatment analyses were performed from 2015 onwards. Kaplan–Meier methods were used for overall survival (OS). Factors associated with OS and systemic anti-cancer therapy (SACT) treatment were assessed using multivariate statistical models. Results Of 1524 patients diagnosed with NSCLC at IPO-Porto, 1008 patients had advanced disease (stage IIIB: 10.1%, 154/1524, stage IV: 56.0%, 854/1524). For those with advanced disease, median age was 65 years (range: 21–92) and 75.6% (762/1008) were male. Median OS (interquartile range [IQR]) was 11.4 (5.2–26.9) months for stage IIIB and 6.3 (2.4–15.0) months for stage IV. Factors associated with decreased risk of death included female sex and epidermal growth factor receptor gene (EGFR)/anaplastic lymphoma kinase gene (ALK) mutations/rearrangements; factors associated with increased risk of death included older age and stage IV disease. Among patients diagnosed in 2015 or 2016, 75.8% (297/392) received ≥1 line of SACT. Platinum-based chemotherapy was the most common first-line therapy (non-squamous cell carcinoma [NSQ]: 72.9%; squamous cell carcinoma [SQ] 87.3%, 55/63; patients with EGFR/ALK mutations/rearrangements primarily received tyrosine kinase inhibitors). The likelihood of receiving SACT was lower in older patients and those diagnosed with stage IV disease. Patients not receiving SACT had poor survival outcomes (median OS [IQR]: NSQ, 1.8 [1.1–3.1] months; SQ, 2.3 (1.3–3.4) months), while median OS (IQR) in SACT-treated patients was 12.6 (6.1–24.5) months for NSQ and 10.3 (5.7–15.9) months for SQ. Conclusions This real-world data analysis from a large Portuguese oncology hospital demonstrates a high disease burden for advanced NSCLC in the pre-immunotherapy era, with nearly one-quarter of patients not receiving SACT. Even in patients receiving SACT, median survival was only about 1 year.

show abstract

“…12 EGFR is reported to be overexpressed in 40-80% of NSCLC cases and its mutations in NSCLC are commonly found in people with East Asian ethnicity, adenocarcinoma histological subtype, females and nonsmokers. 11,17 Studies 18,19 have reported that most EGFR mutations occur in exons 18-22 of the tyrosine kinase domains, with the most common mutation being exon 19 deletions and a point mutation in exon 21 (L858R). Furthermore, there are other rare EGFR mutations including substitutions such as glycine 719 with serine, cysteine or alanine in exon 18, which confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs), or mutations associated with resistance to first-generation TKIs such as the T790M mutation in exon 20 or insertions in exon 20.…”

Section: Epidermal Growth Factor Receptor (Egfr)mentioning

confidence: 99%

A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy

Osei

Lumini

Gunasekara³

et al. 2019

J Radiother Pract

View full text Add to dashboard Cite

Introduction: Lung cancer has a high mortality rate mainly due to the lack of early detection or outward signs and symptoms, thereby often progressing to advanced stages (e.g., stage IV) before it is diagnosed. However, if lung cancers can be diagnosed at an early stage and also if clinicians can prospectively identify patients likely to respond to specific treatments, then there is a very high potential to increase patients’ survival. In recent years, several investigations have been conducted to identify cancer biomarkers for lung cancer risk assessment, early detection and diagnosis, the likelihood of identifying the group of patients who will benefit from a particular treatment and monitoring patient response to treatment. Materials and Methods: This paper reports on the review of 19 current clinical and emerging biomarkers used in risk assessment, screening for early detection and diagnosis and monitoring the response of treatment of non-small-cell lung cancers. Conclusion: The future holds promise for personalised and targeted medicine from prevention, diagnosis to treatment, which take into account individual patient’s variability, though it depends on the development of effective biomarkers interrogating the key aberrant pathways and potentially targetable with molecular targeted or immunologic therapies. Lung cancer biomarkers have the potential to guide clinical decision-making since they can potentially detect the disease early, measure the risk of developing the disease and the risk of progression, provide accurate information of patient response to a specific treatment and are capable of informing clinicians about the likely outcome of a cancer diagnosis independent of the treatment received. Moreover, lung cancer biomarkers are increasingly linked to specific molecular pathway deregulations and/or cancer pathogenesis and can be used to justify the application of certain therapeutic or interventional strategies.

show abstract

Epidemiological Characteristics,EGFRStatus and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study

Cited by 12 publications

References 22 publications

Epidemiology of lung cancer in Northern Greece: An 18- year hospital-based cohort study focused on the differences between smokers and non-smokers

Epidemiology of lung cancer in Northern Greece: An 18- year hospital-based cohort study focused on the differences between smokers and non-smokers

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy

Contact Info

Product

Resources

About